Dermatology firm Creabilis has appointed Catherine Moukheibir as chairman of its board of directors.
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
Commenting on her appointment, Moukheibir said: “I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company’s development.
“The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis’ pipeline and its unique low systemic exposure platform technology.”
Moukheibir has a wide range of experience in aligning corporate goals with financial strategy.
After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at Ablynx and member of the management board at Innate Pharma.
Last November, Moukheiber was also named as an observer to Zealand’s board of directors.